The US Department of Health and Human Services (HHS) has announced plans to withdraw a policy put in place by the previous administration that limited the authority of the US Food and Drug Administration (FDA) to review lab-developed Covid-19 tests. The policy announced in August last year determined that the FDA should not carry out premarket review, including premarket approval or 510(k) clearance and emergency use authorisation of laboratory-developed tests (LDTs), even when poor performance is reported. Prior to August 2020, laboratories had to file applications to create and use their Covid-19 tests, CNN reported.
US-based molecular diagnostic assay provider Biocept has recorded a 165% year-on-year rise in revenues to $17.5m in Q3 2021, driven by higher reverse transcription-polymerase chain reaction (RT-PCR) Covid-19 testing. For Q3 2021, RT-PCR Covid-19 tests alone generated revenue of $16.5m with over 660,000 samples tested since June last year. Testing volumes rose during the third quarter due to the emergence of the SARS-Cov-2 Delta variant, the company reported.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cordant Health Solutions has collaborated with US-based incubator RAIN to offer Covid-19 testing for businesses, schools and other institutions. Cordant’s offering includes reverse transcription-polymerase chain reaction (RT-PCR) testing using saliva and nasal specimens collected from symptomatic and asymptomatic people at home or at a testing site and processed at the company’s Tacoma lab. The company had also introduced a low-cost RT-PCR pooled surveillance testing method for bigger groups. These two methods deliver results in 24 hours. Cordant’s over-the-counter rapid antigen and antibody tests for home or office usage provide results in 15 minutes.
